BEAT - BioTelemetry, Inc.
| Previous Close | 77.59 |
| Open | 77.72 |
| Bid | 76.73 x 900 |
| Ask | 76.81 x 900 |
| Day's Range | 76.61 - 78.50 |
| 52 Week Range | 29.85 - 80.92 |
| Volume | 303,331 |
| Avg. Volume | 597,746 |
| Market Cap | 2.556B |
| Beta (3Y Monthly) | 1.58 |
| PE Ratio (TTM) | 161.24 |
| EPS (TTM) | 0.48 |
| Earnings Date | Feb 21, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.00 |
- Zacks•5 days ago
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
BioTelemetry (BEAT) closed at $76.01 in the latest trading session, marking a -0.38% move from the prior day.
- Zacks•5 days ago
BioTelemetry (BEAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•8 days ago
BioTelemetry, Inc. to Release Fourth Quarter 2018 Earnings Results on February 21, 2019
MALVERN, Pa., Feb. 11, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2018 earnings on Thursday, February 21 at 4:00 PM Eastern Time. The.
- Investor's Business Daily•8 days ago
Salesforce Leads 4 Top Stocks In Buy Range With Rising Earnings Estimates
Salesforce, Splunk, WWE and BioTelemetry stock are in buy zones. The top stocks boast rising earnings estimates, a rare trait in 2019.
- Zacks•12 days ago
BioTelemetry (BEAT) Gains As Market Dips: What You Should Know
In the latest trading session, BioTelemetry (BEAT) closed at $73.52, marking a +0.05% move from the previous day.
- Simply Wall St.•12 days ago
Should You Care About BioTelemetry, Inc.’s (NASDAQ:BEAT) Investment Potential?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we are going to look atRead More...
- Zacks•14 days ago
BioTelemetry (BEAT) Upgraded to Buy: Here's Why
BioTelemetry (BEAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•14 days ago
BioTelemetry (BEAT) Hits 52-Week High, Can the Run Continue?
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks•18 days ago
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
BioTelemetry (BEAT) closed at $72.34 in the latest trading session, marking a +0.72% move from the prior day.
- GlobeNewswire•21 days ago
Investor Expectations to Drive Momentum within Dollar General, Zayo Group, Cabot Oil & Gas, Sangamo Therapeutics, BioTelemetry, and Dean Foods — Discovering Underlying Factors of Influence
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- American City Business Journals•22 days ago
BioTelemetry agrees to buy California-based medical device company for $65M
Medical device company BioTelemetry Inc. has agreed to buy California-based Geneva Healthcare, a provider of remote monitoring for implantable cardiac devices, for $45 million with a promise of an additional $20 million over time. Pasadena, Calif.-based Geneva is an early stage company that has developed a cloud-based platform that aggregates data from the device manufacturer systems, enabling the company to remotely monitor all of a physician’s patients with implantable cardiac devices such as pacemakers, defibrillators and loop recorders. Geneva raised over $6 million in a private offering in 2016 and in its first full year of commercialization last year, the company reached profitability and reported $6 million of revenue. Malvern-based BioTelemetry (NASDAQ: BEAT) specializes in mobile and wireless medical technology used for remote cardiac monitoring, mobile blood glucose monitoring and centralized medical imaging.
- GlobeNewswire•22 days ago
BioTelemetry, Inc. to Acquire Geneva Healthcare, Inc.
BioTelemetry, Inc. (BEAT), the leading remote and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, and Geneva Healthcare, Inc. (“Geneva”), the leading provider of remote monitoring for implantable cardiac devices are pleased to announce that the companies have entered into a definitive merger agreement whereby BioTelemetry will acquire Geneva. An early stage company, Geneva has developed a proprietary cloud-based platform that aggregates data from the leading device manufacturer systems, enabling the company to remotely monitor all of a physician’s patients with implantable cardiac devices such as pacemakers, defibrillators and loop recorders.
- Investor's Business Daily•24 days ago
Dow Jones Rises 3,100 Points From Dec. 26 Low; 6 Top Stocks Break Out
The major indexes have shown strong gains in January. Friday was no exception. Bullish breakouts emerged. The Dow Jones rose a 5th straight week.
- Zacks•25 days ago
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.
- Investor's Business Daily•26 days ago
IBD 50 Stocks To Watch: Why It's Hard To Beat This Setup For BioTelemetry Stock
BioTelemetry stock ranks among top stocks to watch as it carves out a new base, and this new setup could be hard to beat.
- Zacks•26 days ago
NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y
NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.
- Zacks•26 days ago
Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally
Solid overseas growth boosts Varian's (VAR) fiscal Q1 results.
- Zacks•26 days ago
PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong
PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.
- Zacks•26 days ago
Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid
Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.
- Zacks•27 days ago
Top Ranked Momentum Stocks to Buy for January 23rd
Top Ranked Momentum Stocks to Buy for January 23rd
- Zacks•29 days ago
Teladoc Expands Services with Virtual Back Pain Treatment
Teladoc's (TDOC) new addition of virtual back pain treatment will broaden its suite of products and services.
- Zacks•last month
BioTelemetry (BEAT) is a Great Momentum Stock: Should You Buy?
Does BioTelemetry (BEAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks•last month
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
BioTelemetry (BEAT) closed the most recent trading day at $68.16, moving -1.91% from the previous trading session.
- Zacks•last month
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
Is (BEAT) Outperforming Other Medical Stocks This Year?
